The impact of dose on the real-world effectiveness of vortioxetine in outpatients with mdd in greece. (13th April 2021)

• Record Type: Journal Article
• Authors: Papalexi, E.; Kakkavas, P.; Vassos, D.; Mylonaki, T.; Partsafyllidis, D.; Mageiria, S.; Nestoris, C.; Galanopoulos, A.; Ettrup, A.
• Is Part Of: European psychiatry. Volume 64:Supplement 1(2021)
• Page Start: S337
• Page End: S338
• Publication Date: 2021-04-13
• Subjects: Non-interventional -- Vortioxetine -- Depression -- Dose; Psychiatry -- Periodicals; Mental illness -- Periodicals; Electronic journals; 616.89
• DOI: 10.1192/j.eurpsy.2021.905
• Languages: English
• ISSNs: 0924-9338

Abstract

Abstract : Introduction: The current treatment goal in Major Depressive Disorder (MDD) is functional recovery (Zimmerman M et al, 2012). However, finding the "right dose for the right patient" may be challenging and the dose-response relationship for antidepressant efficacy remains controversial (Hieronymus F et al, 2016). Efficacy evaluated by MADRS increases with higher vortioxetine doses, based on meta-analysis data (Thase ME et al, 2016). Objectives: The aim of this exploratory analysis was to assess the impact of different doses on vortioxetine effectiveness in clinical practice in Greece. Methods: In this non-interventional study, open-label vortioxetine was administered at a flexible dosage (5-20 mg/d). Patients receiving 5/10 mg vortioxetine (group A), at the end of the study, were compared to patients receiving 15/20mg vortioxetine (group B). At baseline, 1 and 3 months, depressive symptoms and functioning were assessed by MADRS and SDS. Multiple regression was used for the statistical analyses. Results: The study included 336 MDD patients. At the end of the study, 64.3% (n=200) of patients were receiving 15/20 mg vortioxetine. Higher vortioxetine dose at month 3 was significantly correlated with higher MADRS total score at baseline (p<0.001). SDS total score change from baseline to month 3 was significantly associated with vortioxetine dose (p<0.001), with group A and group B showing improvements of -9.2±8.2 and -12.1±6.0, respectively- whereas such association was not observed for MADRS total score. Conclusions: In conclusion, patients with more severe depressive symptoms were treated with higher antidepressant doses. However, beyond symptom improvement, vortioxetine effectiveness on patient functioning seems to increase with higher doses. Conflict of interest: A. Galanopoulos and E. Papalexi are full-time employees in Lundbeck Hellas. A. Ettrup is a full-time employee in H. Lundbeck A/S.